Anti-FBXW7 antibody [EPR25306-266],Abcam,AB325271
Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .
Host
Rabbit
Reactivity
Human
Application
IP
Platform ID
BAB863331133
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins (PubMed : 17434132, PubMed : 22748924, PubMed : 26976582, PubMed : 28727686, PubMed : 34741373, PubMed : 35395208). Recognizes and binds phosphorylated sites/phosphodegrons within target proteins and thereafter brings them to the SCF complex for ubiquitination (PubMed : 17434132, PubMed : 22748924, PubMed : 26774286, PubMed : 26976582, PubMed : 28727686, PubMed : 34741373). Identified substrates include cyclin-E (CCNE1 or CCNE2), DISC1, JUN, MYC, NOTCH1 released notch intracellular domain (NICD), NFE2L1, NOTCH2, MCL1, MLST8, RICTOR, and probably PSEN1 (PubMed : 11565034, PubMed : 11585921, PubMed : 12354302, PubMed : 14739463, PubMed : 15103331, PubMed : 17558397, PubMed : 17873522, PubMed : 22608923, PubMed : 22748924, PubMed : 25775507, PubMed : 25897075, PubMed : 26976582, PubMed : 28007894, PubMed : 28727686, PubMed : 29149593, PubMed : 34102342). Acts as a negative regulator of JNK signaling by binding to phosphorylated JUN and promoting its ubiquitination and subsequent degradation (PubMed : 14739463). Involved in bone homeostasis and negative regulation of osteoclast differentiation (PubMed : 29149593). Regulates the amplitude of the cyclic expression of hepatic core clock genes and genes involved in lipid and glucose metabolism via ubiquitination and proteasomal degradation of their transcriptional repressor NR1D1; CDK1-dependent phosphorylation of NR1D1 is necessary for SCF(FBXW7)-mediated ubiquitination (PubMed : 27238018). Also able to promote 'Lys-63'-linked ubiquitination in response to DNA damage (PubMed : 26774286). The SCF(FBXW7) complex facilitates double-strand break repair following phosphorylation by ATM : phosphorylation promotes localization to sites of double-strand breaks and 'Lys-63'-linked ubiquitination of phosphorylated XRCC4, enhancing DNA non-homologous end joining (PubMed : 26774286). See full target information FBXW7
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
- Products>Trial Size Antibodies
Please provide the required information below so that we can quickly source your products.